Last reviewed · How we verify

Ropivacaine + Tramadol

Aga Khan University · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while tramadol inhibits monoamine reuptake and activates opioid receptors to provide analgesia.

Ropivacaine blocks sodium channels to provide local anesthesia, while tramadol inhibits monoamine reuptake and activates opioid receptors to provide analgesia. Used for Local and regional anesthesia with postoperative pain management, Infiltration anesthesia for surgical procedures.

At a glance

Generic nameRopivacaine + Tramadol
SponsorAga Khan University
Drug classLocal anesthetic + opioid analgesic combination
TargetVoltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine is a local anesthetic that reversibly blocks voltage-gated sodium channels in nerve fibers, preventing action potential propagation and sensory transmission in the infiltrated area. Tramadol is an analgesic that works through dual mechanisms: inhibition of norepinephrine and serotonin reuptake, and weak agonism at mu-opioid receptors. This combination provides both local anesthetic and systemic analgesic effects for pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: